International Journal of Medical Investigation
Volume 2, Issue 2 (June 2013)
Int J Med Invest 2013, 2(2): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Gonçalves B B, de Alencar R B, Neto M L R, de Alencar M D F B. MECHANISMS OF HYPERCOAGULABILITY PROMOTED BY ORAL COMBINED CONTRACEPTIVES. Int J Med Invest 2013; 2 (2)
URL: http://intjmi.com/article-1-39-en.html
URL: http://intjmi.com/article-1-39-en.html
Bruno Barros Gonçalves * 
, Renata Bezerra de Alencar , Modesto Leite Rolim Neto , Maria de Fátima Bezerra De Alencar
, Renata Bezerra de Alencar , Modesto Leite Rolim Neto , Maria de Fátima Bezerra De Alencar
School of Public Health of the State of Ceará, Fortaleza, CE, Brazil
Abstract: (11223 Views)
Background: Hormonal contraceptive pills are the most used reversible method for familiar planning in Brazil. The combined pill, with synthetic analogs of estrogen and progestin, is employed by 25% of Brazilian female population. Its use provokes an increase of blood pressure levels, takes patient to a hipercoagulability state and predisposes her to thromboembolic events. Purposes: We aimed to describe mechanisms of hypercoagulability promoted by oral combined contraceptives, to analyze the relative risk of cardiovascular events within users and to list the most common circulatory pathologies in these patients.
Methods: Three virtual medical databases were surveyed (Pubmed/Medline, BVS/LILACS and Scielo). Twelve studies were selected: clinical trials, case reports and articles of indexed medical periodic originally published in Portuguese and English about synthetic hormones, oral contraception, coagulation disorders and cardiovascular morbimortality. Results: Synthetic estrogen promotes an increase of some clotting factors’ levels (VII, VIII, IX, X, XII, XIII and fibrinogen), such as a reduction of their inhibitors (S protein and antithrombin). Because of this, etinilestradiol is the component most related to venous thrombosis and ischemic diseases of brain and heart. It also improves the releasing of hepatic angiotensinogen, taking to a increase of blood pressure levels. Conclusions: The prescription of oral combined contraceptives needs criteria, notably due to adverse effects of etinilestradiol. It is recommended to avoid the administration of these drugs for patients elder than 35 year-old or with risk factors. For these patients, the use of progestagen-only pills seems to be safer.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |